Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Study of Efficacy and Safety of Brodalumab Compared With Placebo and Ustekinumab in Moderate to Severe Plaque Psoriasis Subjects (AMAGINE-2)

This study has been terminated.
(Sponsor decision)
Sponsor:
Information provided by (Responsible Party):
Amgen
ClinicalTrials.gov Identifier:
NCT01708603
First received: September 12, 2012
Last updated: July 27, 2015
Last verified: July 2015
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has been terminated.
  Estimated Study Completion Date: August 2015
  Primary Completion Date: September 2014 (Final data collection date for primary outcome measure)
  Certification or Request for Extension to Delay Results Received: April 20, 2015
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):